[go: up one dir, main page]

EA201791736A1 - Комбинированная терапия для лечения рака - Google Patents

Комбинированная терапия для лечения рака

Info

Publication number
EA201791736A1
EA201791736A1 EA201791736A EA201791736A EA201791736A1 EA 201791736 A1 EA201791736 A1 EA 201791736A1 EA 201791736 A EA201791736 A EA 201791736A EA 201791736 A EA201791736 A EA 201791736A EA 201791736 A1 EA201791736 A1 EA 201791736A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
combined therapy
cancer
recurrence
progression
Prior art date
Application number
EA201791736A
Other languages
English (en)
Inventor
Ричард Лаботка
Эндрю Фергус
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201791736A1 publication Critical patent/EA201791736A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение относится к способам лечения рака или предотвращению рецидива или прогрессирования рака, включающим введение пациенту анти-CD38-антитела и ингибитора протеасом.
EA201791736A 2015-02-17 2016-02-16 Комбинированная терапия для лечения рака EA201791736A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562117283P 2015-02-17 2015-02-17
PCT/US2016/018070 WO2016133903A2 (en) 2015-02-17 2016-02-16 Combination therapy for cancer treatment

Publications (1)

Publication Number Publication Date
EA201791736A1 true EA201791736A1 (ru) 2017-12-29

Family

ID=56689146

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791736A EA201791736A1 (ru) 2015-02-17 2016-02-16 Комбинированная терапия для лечения рака

Country Status (8)

Country Link
US (5) US20180235986A1 (ru)
EP (1) EP3258965A4 (ru)
JP (3) JP2018506550A (ru)
CN (1) CN107249635A (ru)
CA (1) CA2976696A1 (ru)
EA (1) EA201791736A1 (ru)
MA (1) MA41555A (ru)
WO (1) WO2016133903A2 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
EP3297729A4 (en) 2015-05-20 2019-04-10 Janssen Biotech, Inc. ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT-CHAINED AMYLOIDOSES AND OTHER CD38-POSITIVE HEMATOLOGICAL MALIGNITIES
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SI3370770T1 (sl) 2015-11-03 2021-03-31 Janssen Biotech, Inc. Subkutane formulacije protiteles proti CD38 in njihove uporabe
WO2018098348A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3703749A1 (en) 2017-10-31 2020-09-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN115403603A (zh) * 2018-09-14 2022-11-29 成都奥璟生物科技有限公司 一种硼酸酯类药物及其用途
AU2019362868A1 (en) * 2018-10-17 2021-05-13 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-CD38 antibodies
US20200308297A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses
CN113993543B (zh) 2019-06-10 2024-07-12 武田药品工业株式会社 使用抗cd38抗体的组合疗法
JP7428601B2 (ja) * 2020-06-29 2024-02-06 株式会社神戸製鋼所 ガスシールドアーク溶接方法、構造物の製造方法及びシールドガス
EP4080515A1 (en) 2021-04-19 2022-10-26 Roche Diagnostics GmbH A method for classifying an identification tag on a sample tube containing a sample and an automated laboratory system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ586780A (en) * 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
CN102961387B (zh) * 2007-08-06 2016-04-27 米伦纽姆医药公司 蛋白酶体抑制剂
ES2390606T3 (es) * 2007-08-06 2012-11-14 Millennium Pharmaceuticals, Inc. Inhibidores de proteasomas
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
CN103497232A (zh) * 2008-06-17 2014-01-08 米伦纽姆医药公司 硼酸酯化合物及其医药组合物
JP6087283B2 (ja) * 2010-09-27 2017-03-01 モルフォシス・アー・ゲー 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2808565T3 (es) * 2013-03-13 2021-03-01 Sanofi Sa Composiciones que comprenden anticuerpos anti-CD38 y carfilzomib
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies

Also Published As

Publication number Publication date
JP2023130496A (ja) 2023-09-20
JP2021059564A (ja) 2021-04-15
EP3258965A4 (en) 2018-08-29
MA41555A (fr) 2017-12-26
WO2016133903A3 (en) 2017-01-05
US20210369748A1 (en) 2021-12-02
WO2016133903A2 (en) 2016-08-25
US20230201227A1 (en) 2023-06-29
EP3258965A2 (en) 2017-12-27
CA2976696A1 (en) 2016-08-25
US20220184103A1 (en) 2022-06-16
US20210137955A1 (en) 2021-05-13
CN107249635A (zh) 2017-10-13
US20180235986A1 (en) 2018-08-23
JP2018506550A (ja) 2018-03-08

Similar Documents

Publication Publication Date Title
EA201791736A1 (ru) Комбинированная терапия для лечения рака
CY1126855T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου
PH12019501959A1 (en) Therapeutic rna
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
EA201790413A1 (ru) Антитела против tigit
EA201790737A1 (ru) Комбинированная терапия
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201790932A1 (ru) Дозировка и введение нефукозилированных анти-cd40 антител
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
MX379621B (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer
MX373045B (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
EA201791095A1 (ru) Способ лечения рака
EA201692472A1 (ru) Соединения для лечения рака мозга
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
EA201891968A1 (ru) Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MY192385A (en) Methods of treating acute kidney injury